News

Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
This was the stock's third consecutive day of gains.
Investing Snacks17h
Vertex Wins EU OK for CF Drug, Eyes Wider Market
Vertex Pharmaceuticals scored a major win with the EU approval of ALYFTREK, expanding its cystic fibrosis treatment access in ...
Zacks Investment Research on MSN23h
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Zacks Investment Research on MSN1d
Vertex Pharmaceuticals (VRTX) Rises As Market Takes a Dip: Key Facts
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $452.16, moving +1.56% from the previous trading session. This change outpaced the S&P 500's 0.11% loss on the day. Meanwhile, the ...
Vertex Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors despite daily gains
This was the stock's second consecutive day of gains.
EU approves Vertex's next-generation cystic fibrosis drug
Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...
Vertex Pharmaceuticals Incorporated (VRTX) Benefited from the Launch of its New Drug
Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” first quarter 2025 ...
STAT6d
Vaccine policy frays, CDC nominee in the hot seat, & obesity drug side effects
What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the ...